RNS and Reach 21/07/2421 Jul 2025 10:09
OBI are certainly pushing their messaging. Whilst the market seems to be waiting on the FDA decision, there are some interesting points in the announcements:
• “We believe that size of the ICU market is at least as large as the pre-surgical decolonization market. Steriwave offers a resistance-free, rapid approach to reducing infections and improving patient outcomes”
• “ Steriwave currently stands as the only antimicrobial proven to eliminate a broad range of multidrug-resistant pathogens from the nose within minutes, without fostering antimicrobial resistance."
• "As stewardship initiatives lose funding, our technologies provide a scalable, rapid solution that reduces healthcare costs, improves outcomes, and protects society against the rising tide of drug-resistant diseases."